ES2180338T3 - Antagonistas del receptor de crf y metodos relacionados. - Google Patents

Antagonistas del receptor de crf y metodos relacionados.

Info

Publication number
ES2180338T3
ES2180338T3 ES99960363T ES99960363T ES2180338T3 ES 2180338 T3 ES2180338 T3 ES 2180338T3 ES 99960363 T ES99960363 T ES 99960363T ES 99960363 T ES99960363 T ES 99960363T ES 2180338 T3 ES2180338 T3 ES 2180338T3
Authority
ES
Spain
Prior art keywords
crf
related methods
crf receptor
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99960363T
Other languages
English (en)
Inventor
Mustapha Haddach
Jodie Nelson
Brian P Dyck
Zhiqiang Guo
Charles Q Huang
James R Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ES2180338T3 publication Critical patent/ES2180338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Input Circuits Of Receivers And Coupling Of Receivers And Audio Equipment (AREA)

Abstract

Un compuesto que tiene la estructura siguiente: con inclusión de sus estereoisómeros, profármacos y sales farmacéuticamente aceptables, en la cual: n es 1 ó 2; A y C son cada uno independientemente nitrógeno, carbono o CH; B es nitrógeno o CR3; con las condiciones de que al menos uno de A, B y C es nitrógeno; A, B y C no son todos ellos nitrógeno; y A - B o B - C es un enlace doble; X es nitrógeno o CH; Ar es arilo, arilo sustituido, heteroarilo, o heteroarilo sustituido; R es un sustituyente opcional que, en cada caso, es independientemente alquilo, alquilidenilo, arilalquilo o heteroarilalquilo, en el cual m es 0, 1, 2 ¿ o 3 y representa el número de sustituyentes R; R1 es - C(H)0, 1(R4)(R5) o - SO2R5; R2 es hidrógeno o alquilo; R3 es hidrógeno, alquilo o haloalquilo; R4 es hidrógeno, ceto, alquilo, alquilidenilo, o halo; y R5 es un radical de la fórmula - Y - Z - R6, en la cual Y es un alcanodiílo, alcanodiílo sustituido, o un enlace directo, Z es NH, - N(R7), O, S, SO2, C(=O), C(=O)O, OC(=O), NHC(=O), C(=O)NH, NH(SO2), (SO2)NH, NR8C(=O)O, o un enlace directo; R6 es hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo, o heterocicloalquilo sustituido; o R7 y R8 son iguales o diferentes y son independientemente alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, heterociclo, heterociclo sustituido, heterocicloalquilo, o heterocicloalquilo sustituido; o R6 y R7, considerados junto con el átomo de nitrógeno al cual están unidos, forman un anillo heterocíclico o anillo heterocíclico sustituido; o R4 y R5, considerados juntos, forman ciclo - alquilo, cicloalquilo sustituido, cicloalquilcicloalquilo, cicloalquilcicloalquilo sustituido, cicloalquil arilo, cicloalquilarilo sustituido, cicloalquilheterociclo, o ciclo - alquilheterociclo sustituido.
ES99960363T 1998-11-12 1999-11-12 Antagonistas del receptor de crf y metodos relacionados. Expired - Lifetime ES2180338T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19107398A 1998-11-12 1998-11-12
US37083799A 1999-08-09 1999-08-09
US40136499A 1999-09-21 1999-09-21

Publications (1)

Publication Number Publication Date
ES2180338T3 true ES2180338T3 (es) 2003-02-01

Family

ID=27392849

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99960363T Expired - Lifetime ES2180338T3 (es) 1998-11-12 1999-11-12 Antagonistas del receptor de crf y metodos relacionados.

Country Status (17)

Country Link
US (1) US6514982B1 (es)
EP (1) EP1129091B1 (es)
JP (1) JP2002529465A (es)
KR (1) KR20010080990A (es)
CN (1) CN1217945C (es)
AT (1) ATE225349T1 (es)
AU (1) AU755552B2 (es)
CA (1) CA2350642A1 (es)
DE (1) DE69903333T2 (es)
DK (1) DK1129091T3 (es)
ES (1) ES2180338T3 (es)
HK (1) HK1038926B (es)
IL (1) IL142893A0 (es)
NO (1) NO20012194D0 (es)
NZ (1) NZ510955A (es)
PT (1) PT1129091E (es)
WO (1) WO2000027846A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
JP2002529465A (ja) * 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびｃｒｆレセプターアンタゴニストに関する方法
WO2001058489A1 (fr) * 2000-02-14 2001-08-16 Japan Tobacco Inc. Agents prophylactiques/therapeutiques contre le stress postoperatoire
AU2001263288A1 (en) 2000-05-18 2001-11-26 Neurocrine Biosciences, Inc. Crf receptor antagonists
AU2002239589B2 (en) 2000-11-03 2005-04-21 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6583143B2 (en) 2000-12-28 2003-06-24 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
DK1354884T3 (da) 2000-12-28 2008-03-03 Ono Pharmaceutical Co Cyklopenta[d]pyrazolo[1,5-a]pyrimidinforbindelse som CRF-receptorantagonist
MXPA03009930A (es) 2001-04-30 2004-01-29 Glaxo Group Ltd Antagonistas del receptor del factor liberador de corticotropina.
JP2004530702A (ja) * 2001-05-21 2004-10-07 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆ受容体アンタゴニストとしてのトリ−およびテトラアザ−アセナフチレン誘導体
GB0117395D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US7273871B2 (en) 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
MXPA05013917A (es) 2003-06-25 2006-03-09 Ono Pharmaceutical Co Sal de acido metansulfonico de compuesto de pirazolpirimidina, cristal de la misma, y proceso para producirla.
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
CA2535249A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
WO2005063749A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
ES2431314T3 (es) 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Inhibidores de polimerasa vírica
WO2005087775A1 (ja) * 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物
WO2006031322A2 (en) * 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis
RU2009132605A (ru) 2007-02-01 2011-03-10 Астразенека Аб (Se) Производные 5,6,7,8-тетрагидроптеридина в качестве ингибиторов hsp90
EP2414359A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Peri-fused pyrazolo-pyrimidine compounds
ES2540964T3 (es) 2009-06-08 2015-07-15 Takeda Pharmaceutical Company Limited Compuestos de dihidropirrolonaftiridinona como inhibidores de JAK
AU2010339444A1 (en) * 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
CN113416191A (zh) * 2021-04-27 2021-09-21 西安交通大学 一种合成三环骨架2-吡啶酮/2-吡啶亚胺类化合物的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5013737A (en) * 1988-02-22 1991-05-07 American Cyanamid Company 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
DE69323768T2 (de) * 1992-12-17 1999-07-01 Pfizer Pyrrolopyrimidine als crf antagonisten
WO1994013661A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Substituted pyrazoles as crf antagonists
WO1994013643A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having crf antagonist activity
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
JP2891544B2 (ja) 1994-06-16 1999-05-17 ファイザー・インコーポレーテッド ピラゾロおよびピロロピリジン類
ATE182148T1 (de) 1995-05-12 1999-07-15 Neurogen Corp Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
CA2249598A1 (en) 1996-03-26 1997-10-02 Paul Joseph Gilligan Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
PL331602A1 (en) 1996-08-06 1999-08-02 Pfizer Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
CA2263566C (en) * 1996-08-28 2003-09-09 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
CA2265672C (en) 1996-09-16 2008-12-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2002529465A (ja) * 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびｃｒｆレセプターアンタゴニストに関する方法

Also Published As

Publication number Publication date
JP2002529465A (ja) 2002-09-10
DK1129091T3 (da) 2002-11-04
WO2000027846A2 (en) 2000-05-18
PT1129091E (pt) 2003-02-28
AU755552B2 (en) 2002-12-12
HK1038926A1 (en) 2002-05-10
DE69903333T2 (de) 2003-08-07
CN1217945C (zh) 2005-09-07
DE69903333D1 (de) 2002-11-07
NO20012194L (no) 2001-05-03
CN1328559A (zh) 2001-12-26
IL142893A0 (en) 2002-04-21
US6514982B1 (en) 2003-02-04
EP1129091B1 (en) 2002-10-02
WO2000027846A3 (en) 2000-11-16
HK1038926B (zh) 2003-07-18
CA2350642A1 (en) 2000-05-18
AU1725800A (en) 2000-05-29
NO20012194D0 (no) 2001-05-03
EP1129091A2 (en) 2001-09-05
NZ510955A (en) 2003-01-31
KR20010080990A (ko) 2001-08-25
ATE225349T1 (de) 2002-10-15

Similar Documents

Publication Publication Date Title
ES2180338T3 (es) Antagonistas del receptor de crf y metodos relacionados.
ES2196898T3 (es) Antagonistas de receptores de crf y metodos relacionados.
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
DE602005014375D1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
DK1646389T3 (da) Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister
AU1529402A (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
TW200626599A (en) CRF receptor antagonists and methods relating thereto
DE602004020638D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
DE60231386D1 (de) Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
BRPI0417943A (pt) antagonistas de receptor de crf e métodos relacionados para essa finalidade
IL158806A0 (en) Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
AU2001261850A1 (en) Crf receptor antagonists and methods relating thereto
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE602004012318D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren